Ignite Biomedical
OperatingIgnite Biomedical, Inc.
Biotech · Framingham, MA
We are currently in the early development stages of our products, with our TNFi treatment response predictor test passing the first step of test development, analytical validation.
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Cap table
Share counts as of May 1, 2026| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 5,500,000 | 1 | 100.0% | — |
Principal holders% as the filing states it, May 1, 2026
- Claudio Faria2,850,000 Common Stock51.8%of company
- Jake Nichols1,900,000 Common Stock34.5%of company
- Everyone else (not named in filings)13.6%
Sold to the crowd
- Reg CF · Feb 2025Common Stock$168.1K· 59 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
6 people
Claudio obtained his Doctor of Pharmacy from the Massachusetts College of Pharmacy as well as an MPH from the University of Massachusetts. Claudio trained as a Clinical Pharmacist at the Brigham & Women's Hospital in Boston and served as the Director of Clinical Research at the UMass Medical School's State Medicaid Program. He has spent the majority of his career (18 years) working in the Pharmaceutical Industry in various leadership roles focused on product access, drug pricing, medical economics, outcomes research, and product development. He is currently a Partner at Verdant Biosolutions, a life sciences consultancy firm, as well as a member of the Strategic Advisory Board of TheraIndx, a global pre-clinical CRO. Currently he also serves as the Chief Executive Officer and Chairman of Ignite Biomedical, where he was also an original co-founder.
Jake is a pharmacist who has worked in many areas of healthcare including academia, primary care, managed care, and pharmaceutical industry. He received his PharmD from the Massachusetts College of Pharmacy in 2000 and his MBA from UMass Boston in 2007.
Joseph is a thirty year life sciences industry executive with experience across pharmaceutical, biotech and medtech, as well as multiple therapeutic areas. Mr. Boswell is founder and Chief Executive Officer of GenMAV Inc., a healthcare advisory and digital platform firm; President of industry group ACCESS Forum; and serves on multiple boards of directors.
Kimberly Baldwin is currently the Senior Vice President, Value & Access at Ipsen Biopharmaceuticals with over 20 years of experience spanning across Sales, Marketing, and Market Access. She has consistently driven progress in the field with her unwavering dedication and leadership. Kimberly became a member of Ignite Biomedical’s Board of Directors in April 2024, bringing a wealth of knowledge and expertise while collaborating with a remarkable team to fulfill Ignite’s mission and positively impact patients’ lives around the globe.
Patrick is co-founder and Chief Executive Officer of Liquid Biosciences, whose quantitative AI platform illuminates the underlying laws of biology and medicine. Patrick co-founded five additional diagnostic companies, two technology startups, and a hedge fund. He is co-inventor of 8 diagnostic tests, 2 pharmaceutical compounds, plus 75 patents and trade secrets in artificial intelligence, causality inference, and special-purpose algorithms. He was a member of the FDA/MDEpinet Blockchain and AI Task Force, and co-chair of its Artificial Intelligence subcommittee. Patrick has guest lectured at CalTech, MIT, Stanford, Berkeley, USC, and the FDA.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C-ARMay 1, 20260002045356-26-000003EDGAR
- Form C-UJul 30, 20250001665160-25-001346EDGAR
- Form C/AJun 11, 20250001665160-25-001202EDGAR
- Form C-UMay 9, 20250001665160-25-001041EDGAR
- Form C/AApr 24, 20250001665160-25-000758EDGAR
- Form C-ARApr 24, 20250001665160-25-000759EDGAR
- Form C-UMar 3, 20250001665160-25-000345EDGAR
- Form CFeb 13, 20250001665160-25-000246EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.